These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23929905)

  • 41. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer.
    Ost P; De Troyer B; Fonteyne V; Oosterlinck W; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1316-22. PubMed ID: 20675081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to "the impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy" (Int J Radiat Oncol Biol Phys 2011;79:379-384).
    Oymak E; Onal C
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1603; author reply 1603-4. PubMed ID: 21740997
    [No Abstract]   [Full Text] [Related]  

  • 43. Medicare physician referral patterns.
    Shea D; Stuart B; Vasey J; Nag S
    Health Serv Res; 1999 Apr; 34(1 Pt 2):331-48. PubMed ID: 10199679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose escalation using a hypofractionated, intensity-modulated radiation therapy boost for localized prostate cancer: preliminary results addressing concerns of high or low alpha/beta ratio.
    Shridhar R; Bolton S; Joiner MC; Forman JD
    Clin Genitourin Cancer; 2009 Oct; 7(3):E52-7. PubMed ID: 19815482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinician's guide to prostate IMRT plan assessment and optimisation.
    Martin JM; Frantzis J; Eade T; Chung P
    J Med Imaging Radiat Oncol; 2010 Dec; 54(6):569-75. PubMed ID: 21199436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia.
    Odrazka K; Dolezel M; Vanasek J; Vaculikova M; Zouhar M; Sefrova J; Paluska P; Vosmik M; Kohlova T; Kolarova I; Navratil P; Brodak M; Prosvic P; Hoffmann P
    Int J Urol; 2010 Sep; 17(9):784-90. PubMed ID: 20604816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relative costs of specialist services in a family practice population.
    Norton PG; Nelson W; Rudner HL; Dunn EV
    CMAJ; 1985 Oct; 133(8):759-61. PubMed ID: 4042059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone.
    Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin JK; Lizarde J; Macedo JC; Ravera J; Tokita KM
    Brachytherapy; 2010; 9(4):341-8. PubMed ID: 19853534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer.
    Zelefsky MJ; Yamada Y; Kollmeier MA; Shippy AM; Nedelka MA
    Eur Urol; 2008 Jun; 53(6):1172-9. PubMed ID: 18222596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Formation of combined urology and radiation oncology practices: objective data from radiation oncologists for rationale.
    Schilling PJ
    Am J Clin Oncol; 2011 Jun; 34(3):289-91. PubMed ID: 20805740
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.
    Franiel T; Lüdemann L; Taupitz M; Böhmer D; Beyersdorff D
    Radiother Oncol; 2009 Nov; 93(2):241-5. PubMed ID: 19748143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intensity-modulated radiation therapy: supportive data for prostate cancer.
    Cahlon O; Hunt M; Zelefsky MJ
    Semin Radiat Oncol; 2008 Jan; 18(1):48-57. PubMed ID: 18082588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A significant decrease in rectal volume and diameter during prostate IMRT.
    Anderson NS; Yu JB; Peschel RE; Decker RH
    Radiother Oncol; 2011 Feb; 98(2):187-91. PubMed ID: 21269715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer.
    Sheinbein C; Teh BS; Mai WY; Grant W; Paulino A; Butler EB
    Urology; 2010 Sep; 76(3):728-33. PubMed ID: 19616279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intensity modulated radiation therapy.
    Maddock PG
    Med Health R I; 2006 Feb; 89(2):76-8. PubMed ID: 16583667
    [No Abstract]   [Full Text] [Related]  

  • 58. [Intensity-modulated radiation therapy (IMRT)].
    Mizowaki T
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():412-7. PubMed ID: 22208013
    [No Abstract]   [Full Text] [Related]  

  • 59. A comparison of prostate IMRT and helical tomotherapy class solutions.
    Rodrigues G; Yartsev S; Chen J; Wong E; D'Souza D; Lock M; Bauman G; Grigorov G; Kron T
    Radiother Oncol; 2006 Sep; 80(3):374-7. PubMed ID: 16884799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rectal dose constraints for intensity modulated radiation therapy of the prostate.
    Swanson GP; Stathakis S
    Am J Clin Oncol; 2011 Apr; 34(2):188-95. PubMed ID: 20622649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.